Taysha Gene Therapies
TSHA
195 hedge funds and large institutions have $1.48B invested in Taysha Gene Therapies in 2025 Q4 according to their latest regulatory filings, with 64 funds opening new positions, 62 increasing their positions, 46 reducing their positions, and 22 closing their positions.
231% more call options, than puts
Call options by funds: $7.02M | Put options by funds: $2.12M
191% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 22
71% more capital invested
Capital invested by funds: $866M → $1.48B (+$614M)
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
35% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 46
26% more funds holding
Funds holding: 155 → 195 (+40)
1.19% more ownership
Funds ownership: 97% → 98.2% (+1.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$40.1M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$18.1M |
| 3 |
State Street
Boston,
Massachusetts
|
+$17.3M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$12.8M |
| 5 |
BlackRock
New York
|
+$11.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$38.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$16.8M |
| 3 |
DM
Deerfield Management
New York
|
-$12.9M |
| 4 |
JFG
Jefferies Financial Group
New York
|
-$10.4M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$9.71M |
TSHA Hedge Fund Activity: Q4 2025 in Review
195 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in Taysha Gene Therapies (TSHA) for Q4 2025, worth a combined $1.48B — up 71% from $866M a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new TSHA positions and 22 closed out — a net gain of 42 holders — while 62 added to existing stakes and 46 trimmed.
The largest buyer was Vestal Point Capital, adding an estimated $40.1M. The largest seller was RTW Investments, cutting an estimated $38.6M.
- 195 institutional investors held Taysha Gene Therapies (TSHA) as of Q4 2025, up from 155 in Q3 2025.
- Funds reported $1.48B of Taysha Gene Therapies stock for Q4 2025, up 71% quarter-over-quarter.
- 64 funds opened new Taysha Gene Therapies positions in Q4 2025 and 22 closed out, a net change of +42 holders.
- The largest Taysha Gene Therapies buyer in Q4 2025 was Vestal Point Capital, an estimated $40.1M added.
- The largest Taysha Gene Therapies seller in Q4 2025 was RTW Investments, an estimated $38.6M sold.
Based on aggregated 13F filings for Q4 2025.